granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
Consolidated financial statements Change Increase/(Decrease) For Three Months Period Ended 30 September 2017 2018 THB mm % THB mm % THB mm % Sale Revenue Revenue from selling product under Company’s trademark 1
–2021 Balance by Quarter Change Q2–21 Q1–21 Q2–20 Q2–21 VS Q1–21 Q2–21 VS Q2–20 (Million Baht: MB) (MB) % (MB) % Total revenue 2,081.2 1,824.2 1,187.6 257.0 14.1 893.6 75.2 Total operating expenses
shares in the Company (after the register of paid-up capital). 4.3 Allocating the newly issued shares to Mr. Nuttawut Phowborom up to 13,333,334 shares, at a par value of Baht 0.25 per share 6 Calculated
ตั้งค่าระบบ (system configuration management) ...........................................36 2.8.2 การบริหารจดัการการเปล่ียนแปลง (change management
February 2019 and will be completed in the late 2019. By the way, the Company plans to register its subsidiary within March 2018. After that the Company will select the outsource for designing the building
(after the register of paid-up capital). 4.3 Allocating the newly issued shares to Mr. Nuttawut Phowborom up to 13,333,334 shares, at a par value of Baht 0.25 per share Calculated from the Minimum Price as
ความเสี่ยง (risk treatment) (5) การจัดทำทะเบียนความเสี่ยง (risk register) (6) การติดตามและทบทวนความเสี่ยง (risk monitor and review) (7) การรายงานความเสี่ยง (risk reporting) N/A Yes/Partial/No N/A N/A N/A
CONSTRUCTION EXECUTIVE SUMMARY EXECUTIVE SUMMARY 2 Q1’19 Q4’19 Q1’20 change change Btmn Btmn Btmn y-on-y q-on-q Sales and service income 10,257 11,258 11,223 9.4% (0.3%) EBITDA* 2,413 2,938 3,278 35.8% 11.6% Net